{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:23Z","timestamp":1793978843109,"version":"4.8.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Adverse metabolic profile manifested as metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity affect the development and prognosis of heart failure (HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Question:<\/jats:title>\n                    <jats:p>Whether treatments targeting metabolic derangements such as sodium\u2013glucose cotransporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) are associated with improved outcomes patients with both HF and MASLD or obesity warrants investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>This retrospective study included 7 propensity score matched cohort analyses using deidentified electronic health record data from the TriNetX global health research network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measures and Outcomes:<\/jats:title>\n                    <jats:p>We evaluated the associations between MASLD, obesity, and the use of SGLT2 inhibitors or GLP-1 receptor agonists with adverse outcomes in patients with HF. Cohorts were defined based on combinations of comorbidities (HF subtype, MASLD, obesity, diabetes status) and medication exposure. Time-to-event outcomes with the Kaplain\u2013Meier method and with Cox proportional hazards models for the calculation of hazard ratios (HRs) and 95% confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among patients with HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction, MASLD was consistently linked to increased risk of nonfatal cardiovascular events, including HF (HR = 1.09,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 and HR = 1.23,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), myocardial infarction (HR = 1.03,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.07 and HR = 1.08,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and stroke (HR = 1.04,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.08 and HR = 1.07,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.07). Use of SGLT2 inhibitors in HFpEF and MASLD patients with or without diabetes was associated with reduced all-cause mortality (HR = 0.76,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 and HR = 0.69,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and major cardiovascular events. GLP-1 receptor agonists demonstrated a significant survival benefit (HR = 0.38,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) in obese patients with HFpEF and MASLD without diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with HFpEF, pharmacologic interventions targeting metabolic pathways demonstrate meaningful cardioprotective effects, especially in metabolically vulnerable subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mjt.0000000000002139","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:00:18Z","timestamp":1778101218000},"page":"e469-e475","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Improved Survival With Sodium\u2013Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Heart Failure With Preserved Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1097","volume":"33","author":[{"given":"Nikolaos-Iason","family":"Tepetes","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Athanasopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Konstantaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Batziou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Soranidis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Kostakou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Stamatelopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; and"},{"name":"Division of Cardiovascular Diseases, University of Iowa Hospitals and Clinics, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"R1-20261106","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J"},{"key":"R2-20261106","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3390\/ijms25052484","article-title":"Potential mechanisms of the protective effects of the cardiometabolic drugs type-2 sodium-glucose transporter inhibitors and glucagon-like peptide-1 receptor agonists in heart failure","volume":"25","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R3-20261106","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2023.04.035","article-title":"Chapter 2: clinical and mechanistic potential of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction","volume":"137","author":"Ostrominski","year":"2024","journal-title":"Am J Med"},{"key":"R4-20261106","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2023.04.019","article-title":"Chapter 3: clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure","volume":"137","author":"Greene","year":"2024","journal-title":"Am J Med"},{"key":"R5-20261106","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10741-021-10186-7","article-title":"Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions","volume":"28","author":"Passantino","year":"2023","journal-title":"Heart Fail Rev"},{"key":"R6-20261106","first-page":"422","article-title":"Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice","volume":"112","author":"Dalpiaz","year":"2026","journal-title":"Heart"},{"key":"R7-20261106","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.3390\/ijms232314598","article-title":"Treatment of HFpEF beyond the SGLT2-Is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients?","volume":"23","author":"Belli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R8-20261106","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"R9-20261106","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"key":"R10-20261106","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/apt.18502","article-title":"Glucagon-like peptide-1 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20261106","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"R12-20261106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjmed.2025.06.039","article-title":"SGLT2 inhibitors and cardiovascular outcomes in MASLD: a real-world retrospective cohort study","volume":"139","author":"Nhat","year":"2026","journal-title":"Am J Med"},{"key":"R13-20261106","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R14-20261106","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.3567","article-title":"Metabolic dysfunction\u2010associated steatotic liver disease is associated with increased risks of heart failure","volume":"27","author":"Chang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"R15-20261106","doi-asserted-by":"crossref","first-page":"103845","DOI":"10.4330\/wjc.v17.i2.103845","article-title":"Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: twin challenges, one metabolic solution","volume":"17","author":"Lian","year":"2025","journal-title":"World J Cardiol"},{"key":"R16-20261106","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"R17-20261106","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"R18-20261106","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0000000000002139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:00:28Z","timestamp":1793977228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0000000000002139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000002139","relation":{},"ISSN":["1536-3686","1075-2765"],"issn-type":[{"value":"1536-3686","type":"electronic"},{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}